European Medicines Agency jeopardizes investments in drug development
The heart of a marketing authorisation application is the pre-clinical and clinical data that proves the drug’s safety and efficacy. This data is collected through substantial investments in time and money. The current and proposed policies of the European Medicines Agency threaten the confidentiality, and hence the business value, of these investments.
Click on the link above to download this Jones Day briefing.
Sign in or Register to continue reading this article
It's quick, easy and free!
It takes just 5 minutes to register. Answer a few simple questions and once completed you’ll have instant access.Register now
Why register to The Lawyer
In-depth, expert analysis into the stories behind the headlines from our leading team of journalists.
Identify the major players and business opportunities within a particular region through our series of free, special reports.
Receive your pick of The Lawyer's daily and weekly email newsletters, tailored by practice area, region and job function.
More relevant to you
To continue providing the best analysis, insight and news across the legal market we are collecting some information about who you are, what you do and where you work to improve The Lawyer and make it more relevant to you.
News from The Lawyer
Briefings from Jones Day
Jones Day operates a different training system to most City firms. Understanding how it works and why the firm doesn’t just follow the crowd is key to understanding whether it’s a system that’s for you.
For the past 10 months, the US Department of Justice and the Enforcement Division of the Securities and Exchange Commission have advised the public that they are in the process of drafting guidance for companies regarding the requirements of, and prohibitions within, the US Foreign Corrupt Practices Act.
Analysis from The Lawyer
When a firm shouts loudly about a landmark merger, as SJ Berwin did when it joined forces with King & Wood Mallesons, departures are always likely to come under the spotlight.